Halozyme Therapeutics, Inc. · NASDAQ:HALO
Halozyme Therapeutics — Investor Presentation (May 2008)
15 slides from Halozyme Therapeutics's investor presentation, May 15, 2008
Slide 1: Company Overview
) Company Overview May 2008
Slide 2: Safe Harbor
Safe Harbor The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. All statements made in this presentation that are not statements of historical fact constitute forward-looking statements. The matters referred to in forward-looking statements c
Slide 3: HALO Investment Highlights
HALO Investment Highlights Three partnered programs validate rHuPH20 core technology FDA approved product, HYLENEX, with large untapped potential Enhanze Technology partnerships with Roche and Baxter may generate additional cash and royalty payments Five proprietary product candidates target extrace
Slide 4: Multi-Functional rHuPH20 Core Technology can Drive Value in Many Different Ways
HYLENEX: Low dose FDA-approved rHuPH20 drug product for delivery of small molecules and fluids Enhanze Technology: High dose rHuPH20 for delivery of large molecules (e.g., monoclonal antibodies) Proprietary rHuPH20 Combinations: Co-formulation with approved products to generate proprietary HALO prod
Slide 5: Proprietary Product Candidates Target the Matrix
Proprietary Product Candidates Target the Matrix Proprietary rHuPH20 combinations Insulin (diabetes) Bisphosphonate (osteoporosis) Chemophase (bladder cancer) Novel Matrix therapeutics PEGrHuPH20 (cancer) HTI-501 (dermatology)
Slide 6: 1. Insulin Program Highlights
1. Insulin Program Highlights Completed Phase I, prospective, randomized trial designed to assess safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of two different approved insulin products injected SC with and without rHuPH20. Poster presentation at ADA next month We anticipat
Slide 7: 2. Bisphosphonate Program Highlights
2. Bisphosphonate Program Highlights >$4 billion annual market, but long-term compliance is poor due to insufficient efficacy, gastrointestinal toxicity, and difficult dosing regimens; >75% of patients discontinue therapy within 3 years IV BPs are inconvenient to patients and general practitioners h
Slide 8: rHuPH20 Suppresses the Injection Site Reaction
rHuPH20 Suppresses the Injection Site Reaction 1.0 1.5 2.0 2.5 3.0 3.5 4.0 0 10 20 30 40 50 60 Reaction Area mm 2 rHuPH20 Days Post Injection rHuPH20 enzyme rapidly disperses the bisphosphonate rHuPH20 provides injection volume flexibility, allowing full dose to be given without injection site react
Slide 9: 3. Chemophase Program Highlights
3. Chemophase Program Highlights Tumor recurrence rates for superficial bladder cancer are 40-85%; 50% will recur within first year Chemophase may increase absorption of Mitomycin C into the bladder wall to decrease recurrence rates Ongoing Chemophase Phase I/IIa trial successful in determining MTD
Slide 10: 4. PEG-rHuPH20 Program Highlights
4. PEG-rHuPH20 Program Highlights HA-rich halos found on many types of aggressive tumors (breast, prostate, pancreatic) rHuPH20 collapses HA dependent pericellular halos on tumor cells by degrading HA around the cells Enhances chemotherapy access to cancer cells HA TUMOR CELL + Enzyme=Halo degraded
Slide 11: IV PEG-rHuPH20 Degrades Tumor HA and Rapidly Reduces Tumor Interstitial Fluid Pressure
IV PEG-rHuPH20 Degrades Tumor HA and Rapidly Reduces Tumor Interstitial Fluid Pressure IM PC-3 tumor pressure measured 20 minutes prior and for 2 hours following IV injection of 10,000 units of PEG^rHuPH20 (n=3), or Carrier Buffer (n=3) (standard deviation indicated) >80% reduction in tumor IFP With
Slide 12: 5. HTI-501 Matrix Degrading Enzyme Program in Aesthetic Dermatology
TARGET fibrous septae create dimples Fat Cells Fibrous Septae Dimple 5. HTI-501 Matrix Degrading Enzyme Program in Aesthetic Dermatology Cellulite is Caused by Fibrous Septae
Slide 13: HTI-501 is Conditionally Active
fibrous septae create dimples 1. Enzyme injected in active state 2. Enzyme digests fibrous septae 3. Body inactivates enzyme Fat Cells Fibrous Septae 4. Dimple relieved Dimple HTI-501 is Conditionally Active
Slide 14: 2008 Milestones
2008 Milestones Publication of INFUSE-LR data, 1Q08 Presentation of GammaGard Phase I/IIa data, 1Q08 Presentation of Bisphosphonates pre-clinical data, 2Q08 Presentation of PEGrHuPH20 pre-clinical IFP data, 2Q08 Presentation of Insulin Phase I data, ADA, 2Q08 Presentation of Cellulite pre-clinical d
Slide 15: HALO's Unique Investment Thesis
HALO's Unique Investment Thesis Compelling Matrix technology (rHuPH20 and other enzymes) with widespread potential across variety of drug delivery and therapeutic uses Revenue generating assets from partnerships and FDA approved drug product that can help fund growth opportunities Scaleable platform
Halozyme Therapeutics — Investor Presentation (May 2008) on 6ix